Stock MBIO MUSTANG BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-23 EDT 		5-day change 1st Jan Change
0.217 USD -9.58% Intraday chart for Mustang Bio, Inc. -27.69% -83.93%
05-15 Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-02 Mustang Bio, Inc. announced that it has received $3.3 million in funding CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Mustang Bio Announces Closing of $4 Million Public Offering
AQ
Mustang Bio, Inc. announced that it has received $3.3 million in funding
CI
Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants
MT
Mustang Bio Announces Pricing of $4 Million Public Offering
AQ
Mustang Bio : Results of Operations and Financial Condition - Form 8-K
PU
Mustang Bio, Inc. announced that it expects to receive $3.3 million in funding
CI
North American Morning Briefing : Stock Futures Rise Despite Middle East Tensions
DJ
Mustang Bio : Costs Associated with Exit/Disposal - Form 8-K
PU
Mustang Bio : Corporate Presentation
PU
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
AQ
Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
CI
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
AQ
Mustang Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
City of Hope-developed chimeric antigen receptor T cell therapy shows clinical activity in patients with aggressive brain tumors in a Phase 1 trial
AQ
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
AQ
Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma
CI
Mustang Bio : Corporate Presentation
PU
Mustang Bio, Inc Appoints James Murphy as Interim Chief Financial Officer
CI
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MBIO Stock
  4. News Mustang Bio, Inc.